Derm Cases · Dermatology / Surgical dermatology
OSCE — pearly facial nodule: basal cell carcinoma recognition, risk stratification and treatment pathway
An 8-minute OSCE station on nodular BCC morphology, dermoscopy clues, high-risk (H-zone) features, biopsy, surgical margins/Mohs indications, and options for superficial or advanced disease.
On this page
Study tools
Target exams
NEET-PGINICETUSMLEPLABMRCP
Prompt
An 8-minute OSCE station on nodular BCC morphology, dermoscopy clues, high-risk (H-zone) features, biopsy, surgical margins/Mohs indications, and options for superficial or advanced disease.
Brief (to candidate)
A 68-year-old fair-skinned man has a slowly enlarging pearly papule on the left nasal ala for 14 months with a rolled border, arborising telangiectases and central crusting. He has cumulative sun exposure and a prior scalp BCC. You have 8 minutes to recognise the lesion, stratify risk, plan diagnosis and outline management.
Candidate instructions
- Describe nodular BCC morphology and key dermoscopy features.
- Identify high-risk site/subtype factors (H-zone, ill-defined margins).
- Plan appropriate biopsy and distinguish from SCC/melanoma mimics.
- Outline surgical options (standard excision margins vs Mohs).
- Mention non-surgical options for selected low-risk superficial BCC and Hedgehog inhibitors for advanced disease.
- Give safety-net and photoprotection advice.
Examiner checklist (mark each domain / 10)
| Domain | Key actions expected |
|---|---|
| Recognition | Pearly papule/nodule, rolled border, arborising telangiectases, central ulceration ("rodent ulcer") on sun-exposed skin; rare metastasis but local destruction risk[2][4] |
| Dermoscopy | Arborising vessels, blue-grey ovoid nests, spoke-wheel/leaf-like areas, ulceration; subtype-linked features support clinical diagnosis before histology[3] |
| Risk stratification | H-zone (periocular/perinasal/periauricular/ear/scalp), size, recurrent disease, morpheaform/infiltrative/micronodular subtypes = high-risk; consider Gorlin if multiple early BCCs[1][5] |
| Diagnosis | Diagnostic biopsy (shave/punch appropriate for many BCC) confirming basaloid nests with peripheral palisading; full clinical photo-documentation |
| Surgery | Low-risk: excision with ~4–5 mm clinical margins; high-risk/critical-site/recurrent: prefer Mohs micrographic surgery for margin control and tissue sparing[1][2] |
| Non-surgical / advanced | Selected low-risk superficial BCC: topical imiquimod / 5-FU / PDT where appropriate; radiotherapy selected cases (avoid in Gorlin); vismodegib/sonidegib for locally advanced/unresectable; immunotherapy after HHI failure in specialist care[1][5] |
| Communication | Explain local aggressiveness vs low metastatic rate; photoprotection; whole-skin check; urgent pathway if H-zone or ill-defined scar-like plaque |
Model key actions
- Diagnose classic nodular BCC on the nasal ala using morphology ± dermoscopy.[2][3]
- Flag H-zone high-risk site → prioritise Mohs discussion over casual observation.[1]
- Plan tissue diagnosis then definitive margin-controlled treatment; discuss topical options only for appropriate superficial low-risk disease.[1][4]
- Photoprotection, full skin examination, and follow-up for field UV damage.
Common errors
- Dismissing a pearly ulcerated nodule as "just a spot" without biopsy.
- Standard wide excision planning without recognising Mohs indications on the H-zone.
- Using radiotherapy as first choice in suspected Gorlin syndrome.
- Confusing pigmented BCC with melanoma and delaying appropriate biopsy pathway.
- Ignoring cumulative field damage and second primary skin cancers.
References6ShowHide
- [1]Peris K, Fargnoli MC, Kaufmann R, et al. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023. European journal of cancer (Oxford, England : 1990), 2023.PMID 37604067
- [2]Heath MS, Bar A. Basal Cell Carcinoma. Dermatologic Clinics, 2023.PMID 36410973
- [3]Reiter O, Mimouni I, Dusza S, et al. Dermoscopic features of basal cell carcinoma and its subtypes: A systematic review. Journal of the American Academy of Dermatology, 2021.PMID 31706938
- [4]Kim DP, Kus KJB, Ruiz E. Basal Cell Carcinoma Review. Hematology/oncology clinics of North America, 2019.PMID 30497670
- [5]Dika E, Scarfì F, Ferracin M, et al. Basal Cell Carcinoma: A Comprehensive Review. International Journal of Molecular Sciences, 2020.PMID 32759706
- [6]Migden M, Farberg AS, Dummer R, et al. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma J Drugs Dermatol, 2021.PMID 33538567